Nova Eye Medical Limited (ASX:EYE)

Market Cap	48.42M +24.3%
Revenue (ttm)	29.27M +25.5%
Net Income	-9.06M
EPS	-0.04
Shares Out	284.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	292,368
Average Volume	949,707
Open	0.1770
Previous Close	0.1750
Day's Range	0.1700 - 0.1770
52-Week Range	0.0860 - 0.2050
Beta	0.89
RSI	54.38
Earnings Date	Feb 1, 2026

About Nova Eye Medical

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It also engaged in the commercialisation of the subthreshold nano-pulse ophthalmic laser; 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1970
• Employees: 301
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EYE

Financial Performance

In fiscal year 2025, Nova Eye Medical's revenue was 29.27 million, an increase of 25.47% compared to the previous year's 23.33 million. Losses were -9.06 million, 3.06% more than in 2024.